Establishment Labs to Announce Fourth Quarter 2021 Financial Results on March 1

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ending December 31, 2021, on March 1, 2022, before market opens. The company will host a conference call at 8:30 am ET the same day to discuss these results. Established in 2010, the company focuses on women’s health, particularly breast aesthetics and reconstruction, offering innovative silicone gel-filled Motiva Implants^®. Over 2 million of these implants have been distributed across 80 countries, emphasizing its global presence and commitment to advanced healthcare solutions.

Positive

• Establishment Labs has successfully delivered over 2 million Motiva Implants^® since their launch.
• The company operates in over 80 countries, indicating a strong international market presence.

Negative

• None.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2021 before the market opens on Tuesday, March 1, 2022, and will host a conference call at 8:30 am ET that day to discuss those results.

To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13725695. The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants^® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 2.0 million Motiva Implants^® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora^® tissue expander and Motiva MIA^®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant^® and began a clinical trial to support regulatory approval in the United States. Motiva Implants^® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005232/en/

Investor/Media Contact:

Raj Denhoy

415-828-1044

Rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

When will Establishment Labs announce its Q4 2021 financial results?

Establishment Labs will announce its financial results for Q4 2021 on March 1, 2022.

What time is the Establishment Labs conference call scheduled?

The conference call is scheduled for 8:30 am ET on March 1, 2022.

How can I access the conference call for Establishment Labs?

You can participate in the conference call by dialing (877) 407-8037 for U.S. and Canada, or (201) 689-8037 for international calls, using conference ID 13725695.

What is the focus of Establishment Labs' business?

Establishment Labs focuses on improving women's health, particularly in breast aesthetics and reconstruction.

What products does Establishment Labs offer?

Establishment Labs offers advanced silicone gel-filled breast implants branded as Motiva Implants^®.